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Abstract
Objectives—The ability to assess quality of care is a necessary component of continuous quality
improvement. The assessment typically is accomplished by determination of compliance with a
defined set of quality measures (QMs). The objective of this effort was to establish a set of QM for
the assessment of the process of care in JIA.
Methods—A 12 member working group (WG) composed of representatives from the ACR,
AAP, ABP, and ARHP was assembled to guide the project. Delphi questionnaires were sent to
237 health professionals involved in the care of children with juvenile idiopathic arthritis (JIA). A
total of 471 items in 27 domains were identified. The WG met via four live e-meetings during
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which results from the Delphi’s were distilled to a reduced draft set. Each WG member selected a
proposed QM to investigate and present evidence from the literature as to its attributes and
appropriateness for inclusion into the set. Nominal group technique was used to come to
consensus on a proposed set of QMs.
Results—The proposed set contains 12 QMs within four health care domains. Each QM consists
of a statement of (i) the assessment to be completed, (ii) when the first assessment should be
completed and a suggested frequency of assessment during follow-up, (iii) recommendations of
appropriate tools or methods of assessment, and (iv) initial performance goals.
Conclusions—Implementation of the proposed QM set will improve the process of care,
facilitate continuous QI, and eventuate in improved health outcomes of children with JIA.
Keywords
juvenile idiopathic arthritis; quality measures; process of care
Pediatric rheumatology centers are engaged in local quality improvement (QI) efforts in
their centers to varying degrees. Systematic efforts have been pursued at some centers for
years, but for most the efforts are just beginning. Central to this process is the identification
of ‘quality measures’ (QMs, also commonly referred to as ‘quality indicators’). QMs must
be developed in consideration of the evidence that (i) their performance results in improved
health outcomes and evidence and (ii) they are operationally feasible in a variety of clinic
infrastructures. QMs focused on the process of care typically contain a statement of the
assessment to be completed, method for conducting the assessment, frequency of
reassessments during follow-up and initial performance goals. Although some individual
pediatric rheumatology centers have identified QMs and are using them to perform QI, there
is not a uniform QM set relevant to the process of care of children and adolescents with
Juvenile Idiopathic Arthritis (JIA) in widespread use. In this project the focus was on
process of care to facilitate development of a standardized method of assessment of QI
across centers. Once this method is established, then centers will be able to use these data in
the future to develop validated QI measures that focus on patient status and outcomes.
In 2008 the American College of Rheumatology (ACR) provided funding to develop a set of
QMs for use by health care professionals (HCPs) involved in the care of patients with JIA.
The chief objective of the project described herein was to convene representatives from
major North American organizations involved in pediatric rheumatology to work together to
develop a standard set of QMs, based upon existing evidence and clinical experience
focused on the process of care for patients with JIA. The development of this standard set of
QMs was done to (i) facilitate the development of a network of pediatric rheumatology
centers working in a coordinated fashion to improve the outcome of children with JIA, (ii) to
serve as a basis for QI projects for the ACR and other organizations and, (iii) to be used by
the American Board of Pediatrics (ABP), as Part 4 of the requirements for Maintenance of
Certification in Pediatric Rheumatology1.
METHODS
We used a methodology similar to that used by MacLean et al to develop QM for rheumatic
diseases in adults2. A Quality Measures Working Group (WG) was assembled that was
composed of 12 individuals, each selected by their respective organization from the pediatric
rheumatology sections of the American College of Rheumatology (ACR) and the American
Academy of Pediatrics (AAP), the Association of Rheumatology Health Professionals
(ARHP), the American Board of Pediatrics (ABP), the Childhood Arthritis and
Rheumatology Research Alliance (CARRA) Consolidated Registry Committee, the Pediatric
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Rheumatology Improvement Network for Clinical Effectiveness (PRINCES), and two
facilitators experienced in group process and consensus formation techniques. The WG’s
overall charge was to use consensus techniques to develop a QM set, based upon available
evidence and clinical expertise, for the process of care for JIA.
In order to obtain broad-based input regarding health care domains and assessments in those
domains, the WG sent an online Delphi-type3 electronic questionnaire (Delphi 1) to various
stakeholders. The Delphi packets included an explanation of the rationale for need, the
intended purpose of the survey, explanations as to what QMs represent and their intended
use. Recipients were instructed to state what they believed to be the top five measures of
outcome or care in JIA. A total of 237 individuals received the survey, including 170
pediatric rheumatologists, eight advanced practice nurses (APNs) involved in JIA care, and
59 patients and parents, representing 27 states and Prince Edward Island, Canada. Results of
Delphi 1 were reviewed by the WG, which distilled the assessments offered by respondents
including grouping them into domains, during a series of teleconferences employing
nominal group technique (NGT) consensus formation methodology4. Replies that were
redundant or represented the same concept, but stated in a different manner, were combined.
Domains and assessments in the domains were then retained or eliminated based largely
upon feasibility (practicality, ease of use), and face validity (clinical sensibility)5-6.
A second questionnaire survey (Delphi 2) containing a reduced set of domains and
assessments was developed and sent to the same 237 stakeholders, regardless of whether or
not they had replied to Delphi 1. Participants were asked to rank order the reduced number
of domains and assessments within a domain in terms of their perceived relative importance
in assessing quality of care.
Working from these results, a series of four web-based interactive live meetings using iLinc
(available at www.iLinc.com) were held among WG members and facilitators during 2009.
The purposes of these meetings were to come to consensus on the following questions: (1)
should the assessment be retained in the proposed set; (2) do validated methods exist for
conducting the assessment and, if so, should one method be recommended over the others;
(3) when should the first assessment occur, and how frequently should reassessment be done
during follow-up; (4) what proportion of patients with JIA in a given clinical practice should
meet the QM initially, referred to as the ‘initial performance goal’.
Prior to convening the series of live meetings, each WG member chose a specific QM to
investigate by searching the literature and relying on his/her personal clinical expertise in
order to answer the four questions shown above. The intent was to familiarize the WG with
existing evidence of the utility and clinical relevance of each QM, thereby facilitating
consensus-formation and synthesis of a proposed set of recommendations. (The specific
references used to obtain evidence on which to base recommendations made to the group by
individual presenters are given as an Appendix to this manuscript.)
Format of the four live meetings was as follows. A facilitator introduced the topics for
discussion and deliverables (e.g. questions to be addressed) for the call. This was followed
by a presentation of the evidence for each QM by the member who had undertaken the
review. The presenter stated his or her suggested answers to the questions above, and
provided the evidence that formed the basis for their opinions. Following the presentation,
NGT was used to come to consensus about the answers to the questions stated above. In
general, meetings lasted approximately 3 hours and two to three QM were discussed during
each meeting. Facilitators reviewed digital recordings of each meeting, developed a working
document containing QM statements, and circulated it to the entire WG for revision. A
finalized set of recommendations was then produced.
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Response to Delphi 1: Overall response rate to Delphi 1 was 40% (N = 95); 35% for
pediatric rheumatologists, 50% for APNs, and 52% for parents and patients. Among
physician-respondents, 85% were currently treating more than 50 patients with JIA per year.
Responses to Delphi 1 resulted in 471 proposed JIA QMs sorted into 23 domains (Table 1).
Using conference calls, Delphi and NGT, the WG reviewed the 471 QMs for feasibility, face
validity, and redundancy. Item reduction resulted in five domains with a total of 19 quality
measures: (1) disease control, 11 QMs, (2) safety monitoring, 4 QMs, (3) education, 2 QMs,
(4) access/equity/timeliness, one QM and (5) relationship/patient-family satisfaction with
care, one QM.
These five domains and 19 assessments formed the basis for Delphi 2 in which participants
were asked to rank order the domains and, for the three domains that contained more than
one assessment (disease control, safety monitoring, and education), rank order the
assessments within the respective domain.
Response to Delphi 2: Overall response rate was 57% (N = 135): 57% for pediatric
rheumatologists, 100% for APNs and 50% for patients and parents. Of these respondents,
69% had participated in the Delphi 1.
Results from Delphi 2 showed the highest ranking assessments in domains with more than
one assessment were: (1) disease control: (tied) number of joints with active arthritis and
physician global assessment of disease activity; (2) safety monitoring: patients undergo eye
screening according to published guidelines; (3) access/equity/timeliness: time to first
available appointment with a pediatric rheumatologist.
The WG reviewed the Delphi 2 responses, and used NGT to come to consensus on a
working set of QMs. The original five domains and 12 assessments within the domains were
maintained in the working set (Table 2). This working set formed the basis for the four live
web-based consensus conferences aimed at reviewing the evidence for maintaining the
proposed domains and assessments, as well as tools for assessment, frequency of
assessment, and initial and final quality performance goals.
Results of the four live web-based meetings were as follows. During the initial meeting, the
WG decided that five assumptions were necessary in order to specify what categories of JIA
the QMs would be applicable to, and to provide working definitions of the terminology used
in QM statements. These assumptions are shown at the top of Table 3. Consensus was
reached during the live meetings on eight of the resulting QM statements. The remaining
four QMs were re-circulated to WG members in survey format in an attempt to arrive at
consensus. When it became apparent that no consensus among the WG members was
possible, outside opinion was sought from five external board-certified pediatric
rheumatologists chosen by the WG, and with extensive experience in caring for children
with JIA. The proposed set of QMs resulting from the WG meetings and follow-up surveys
are shown in Table 3. A total of 12 QM distributed among four health care domains are
included in the proposed set.
DISCUSSION
Healthcare providers strive to provide good care to their patients by virtue of their training,
and professional ethics; however, this does not necessarily translate into quality outcomes
for the patients. In 1999, the Institute of Medicine (IOM) reported that an estimated 98,000
patients die from medical errors per year in the United States and mandated reformation in
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the healthcare system to reduce the error and improve safety for patients7. The IOM further
recommended that all organizations improve their performance by incorporating care
process and outcome measures into their daily work for improvement and accountability.
The QI movement grew from this and subsequent efforts of the IOM and is now
incorporated into a broad, complex and incompletely coordinated landscape of agencies,
institutions, healthcare insurers, healthcare facilities, etc. Furthermore, the importance of
developing quality measures derives from the contemporary era of mandated quality of care
as set forth in virtually all arenas of medical environment: patient care, education, and
accreditation.
The JIA QM Workgroup was organized with the purpose of developing a core set of QM for
JIA that would be adopted broadly. Moreover, it was thought to be critical that these QM be
developed by those most directly involved in the care of children with JIA-parents, patients
and pediatric rheumatology health care providers. The organizations which the WG
members were drawn from represent the key professional, scientific and accreditation
organizations in pediatric rheumatology. The ABP, in accord with the recommendations of
the Task Force on Competence of the American Board of Medical Specialties (ABMS), has
mandated that all pediatric rheumatologists seeking ABP recertification demonstrate
competency through active participation in quality improvement. Representatives from the
ABP were actively involved in the development of these JIA QMs and will incorporate them
in Maintenance of Certification training and materials. The JIA QM Workgroup chose to
focus on measures of the system or process of care initially to establish regular assessments
of the common important measures of care in a standardized fashion. This is a necessary and
critical first step in QI efforts. Once centers have adopted these process measures we will be
able to move forward as a group with addressing patient outcomes. This work will be
informed and grounded in the results obtained from the current proposed core set of QI
measures for the process of care in JIA.
The domains developed in this project will assess dimensions of care which the IOM
identified as needing improvement. The IOM specified dimensions of quality care include
safety, efficiency, efficacy, patient-centered, equity, and timeliness8. The domains in this
JIA QM set include: 1) Disease Control which reflects effectiveness; 2) Safety Monitoring,
which addresses Safety; 3) Assessment of Self-Efficacy and Patient/Parent Satisfaction
which are central to Patient Centered Care; and lastly 4) Access which incorporates
Timeliness. All of the selected JIA QMs are measurable and were subject to evidence in the
literature. Equity in closing racial and ethnic gaps in health status, recognized as a key area
needing improvement, is an outcome-focused measure, and therefore not included in the
current set of QMs. ‘Initial performance goals’ given in the QM set are based largely on
what the QMWG concluded were reasonable and feasible for most practices to achieve.
Conversely, no ‘ideal performance goal’ is given because continuous QI implies that ever
higher performance goals are to be set, achieved, and then improved upon further.
The JIA QMs developed in this project hopefully will serve as a format for registry
development and initiation of serial data acquisition. This will provide a baseline of data for
the development of quality improvement projects, both for the individual practitioner or as a
collaborative for a group of centers. Many pediatric subspecialty groups, including
neonatology, pulmonology, and critical care medicine have had strategies to conduct quality
improvement through national and regional collaboratives. Benchmarking can be established
as collaborative members are transparent in the data and share best practices. The optimal
result of the quality improvement work done in either setting, individual or collaborative,
will be the improvement of the processes of care which ultimately affects the outcome of the
patient’s disease status. The view of the WG members is that this improvement will be
achieved in a much more efficient and timely manner for JIA if the effort is driven by the
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use of a standardized set of widely adopted QMs. QMs developed in this project provide
parameters but leave latitude for choosing the specific tools or instruments to measure the
assessment. The aim is to have relatively uniform data collection for optimizing the outcome
of quality improvement projects. Broad based efforts in pediatric rheumatology are ongoing
at this time to develop a common JIA registry for longitudinal data collection in JIA patients
in many pediatric rheumatology centers and to develop a sophisticated QI network. The
incorporation of these JIA QMs in both these efforts will enhance the effectiveness of our
shared goal of improving the systems of care for children with JIA so as to improve their
disease, function, and quality of life outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Appendix
Disease Control Domain
Quality Measure #1: Assessment of Arthritis-Related Pain
Pain should be assessed in all patients at the first visit and at each subsequent visit that
occurs at least 7 days apart. (The QMWG recognized two types of pain: (i) acute pain
intensity at a point in time and, (ii) average pain over some period. Here, average pain over a
period of 7 days is what is to be assessed.)
• Tools: In patients 7 years or older, pain should be assessed as an average over the
last 7 days. In patients less than 7 years of age, the parent or guardian should be the
proxy reporter of average pain. Any validated, reliable, age-appropriate tool to
measure average pain may be used.
• Initial Quality Performance Goal: ≥80% of patients receive an assessment of pain
at the first visit and at each subsequent visit if at least 7 days apart.
Quality Measure #2: Rheumatological Joint Count
A full joint count of all 75 joints should be done on all patients at the first visit and at 6
month intervals. (Reduced or weighted joint counts may be acceptable in the future after
these methods have been more fully validated)
• Tools: Included in the QM.
• Initial Quality Performance Goal: ≥80% of initial visits and 6 month interval visits
include a joint count.
Quality Measure #3: Physician’s Global Assessment of Disease Activity (PGA)
A PGA should be completed on all patients at the initial visit and at each subsequent visit.
• Tools: Any validated, reliable method may be used to assess the PGA. An example
is the 0-10 VAS, divided into 0.5 increments9.
• Initial Quality Performance Goal: 80% of initial and subsequent visits include a
PGA.
Quality Measure #4: Assessment of Functional Ability
All patients should receive an assessment of functional ability at the initial visit and at a
minimum of 6 month intervals thereafter.
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• Tools: Any age-appropriate validated and reliable tool for the assessment of
functional ability may be used. An example is the Childhood Health Assessment
Questionnaire10.
• Initial Quality Performance Goal: ≥70% of initial and 6 month interval visits will
include an assessment of functional ability.
Quality Measure #5: Assessment of Health Related Quality of Life (HRQOL)
All patients should receive an assessment of HRQOL at the initial visit and at 6 month
intervals.
• Tools: Any age appropriate, validated, reliable and age-appropriate tool, which is
capable of changing over a 6 month interval, may be used to assess HRQOL.
Examples include the PedsQL™11 and Childhood Health Questionnaire12.
• Initial Quality Performance Goal: ≥70% of initial and 6 month interval visits will
include an assessment of HRQOL.
Quality Measure #6: Eye Examinations and Documentation of Compliance to Guidelines
Either the AAP13 or modified Heiligenhaus14 guidelines for eye examinations should be
followed for patients with any category of JIA. Documentation of compliance to the
guidelines should be performed at every visit at least 3 months apart.
• Tools: No single mechanism for obtaining written or verbal documentation of
compliance is recommended, but should be one that is convenient for the practice,
such as consultation with the ophthalmologist.
• Initial Quality Performance Goal: ≥40% of patients provide documentation of
compliance to the guidelines.
Safety Monitoring Domain
Quality Measure #7: TB Screening in JIA Patients Beginning Biologic Therapy
All patients with JIA will undergo TB screening no longer than 3 months prior to the start of
any biologic therapy and yearly thereafter as long as the patient remains on biologic therapy.
• Tools: TB screening may be done using the standard TB skin test or, if appropriate,
a standard blood test. If, in the clinician’s judgment, the patient is immuno-
compromised and the TB skin test is negative or the patient has received BCG so
that skin test results are in question, a blood assay test is recommended prior to
beginning any biologic therapy.
• Initial Quality Performance Goal: 100% of patients receive TB screening prior to
start of any biologic therapy and yearly thereafter.
Quality Measure #8: Laboratory Monitoring
All JIA patients receiving DMARD or biologic therapy will be monitored for toxicity by
clinical laboratory methods. The minimal frequency of laboratory monitoring for DMARDs
is every 2-4 weeks for the first 3 months of therapy, every 8-12 weeks after 3-6 months, and
every 12 weeks after 6 months of therapy. Guidelines for laboratory monitoring of biologic
therapy are evolving and recommendations in this quality measure will be added in the
future.
• Tools: The minimal laboratory panel for monitoring laboratory toxicity for
DMARDS includes CBC, platelets, and transaminases. CrCl should be assessed in
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new DMARD starts and at regular intervals in patients on cyclosporine or in
patients with known renal disease. Pregnancy testing is at the discretion of the
managing physician.
• Quality Performance Goal: An initial quality performance goal is 70% of patients
receiving DMARDs undergo the recommended laboratory monitoring.
Quality Measure #9: Behavioral Counseling about Toxicity to DMARDS and Biologic
Therapy
Patients engaging in risk-taking behaviors which could have health consequences related to
their medication or disease should receive counseling at each visit. Patients not engaging in
risk-taking behaviors which may have health consequences related to their medication or
disease should receive counseling at least annually.
• Tools: At the discretion of the health care professional.
• Initial Quality Performance Goal. ≥70% of patients receiving DMARDs or
biologics undergo counseling.
Assessment of Self Efficacy and Patient/Parent Satisfaction
Quality Measure #10: Assessment of Self-Efficacy
(self efficacy is the belief that one is capable of performing in a certain manner to attain
certain goals15)
Patients should be assessed for self-efficacy at periodic intervals. The first assessment of
self-efficacy should be ≤ 6 months after the initial visit and every 6 months thereafter.
• Tools: Acceptable tools for assessment of self-efficacy include (i) the General Self-
Efficacy Scale16, (ii) the Children’s Arthritis Self-Efficacy Scale17, and (iii) the
Parent’s Arthritis Self-Efficacy Scale18. Other validated tools may be used.
• Initial Quality Performance Goal: ≥50% of patients are assessed for self-efficacy ≤
6 months after the initial visit, and every 6 months thereafter, if feasible.
Quality Measure #11: Assessment of Patients/Parents Satisfaction with Care
Patients and/or parents should be assessed for their level of satisfaction with the quality of
care provided to them/their child. The first assessment should be done no longer than 1 year
after the initial visit, and annually thereafter. (Because the individual physician is often not
able to influence the patient’s satisfaction with the overall health care delivery system or
insurance company, this QM focuses upon satisfaction with the health care provided by the
physician.)
• Tools: No one specific tool for use in JIA is recommended. Satisfaction may be
assessed using any validated tool such as the Consumer Assessment of Healthcare
Providers and System questionnaire (CAHPS19) or other validated and reliable tool.
• Initial Performance Goal: Satisfaction assessments are received from ≥30% of
patients according to the recommended schedule. (This implies that the physician
has made enough effort to receive satisfaction assessments from ≥30% of the
overall JIA population in the practice.)
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Quality Measure #12: Time to Third-Next Available
As an initial goal, all patients with signs and/or symptoms of JIA should receive an
appointment, based upon the third-next-available20, an average of ≤ 60 calendar days for a
new patient visit from the time of referral. (Timing of follow-up visits is dependent upon
numerous factors, and no recommendation is made here.)
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Table 2
Working set of domains and assessments from the Delphi exercises and working group consensus on
identifying measures for the process of care in JIA*
Disease Control Domain
• Pain management
• Achieve complete disease control within a period of X months
• Number of active joints
• Physician’s global assessment of disease activity
• Physical functional ability
• Quality of life
Safety Monitoring
• All patients undergo eye screening according to published guidelines
• Regular laboratory screening for toxicity to second line therapeutic agents and biologics
• All patients are screened for TB prior to the start of biologic therapy
Education
• Visual numeric scale to assess parent/patient confidence in ability to manage care of children with JIA
Access/Equity/Timeliness
• Time to first available appointment with pediatric rheumatologist
Relationship
• Parent/patient satisfaction with care
*
Some items offered by Delphi participants represent outcomes rather than process of care assessments. Because the focus of this effort was
process of care, such replies were not considered further for inclusion.
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Table 3
Assumptions and summary of the final proposed set of quality measures for the process of care in JIA
Assumptions:
• QMs were developed under the assumption that they would be applicable to all categories of JIA.
• QMs, their frequency of assessment, and performance goals are minimum recommendations. In the spirit of continuous quality
improvement, performance goals should be improved upon continually over time.
• QM in which a timed frequency of assessment (e.g. every 6 months) is recommended implies that if the patient is seen less often
than the recommended assessment schedule, then the assessment will be done at each visit.
• First visit implies first visit to the pediatric rheumatologist after a diagnosis of JIA has been made.
• If a physician practices within an institution or clinic that recommends a frequency and/or method of assessment of QM/s, that is
comparable (and not less stringent) then the local guidelines should be followed in lieu of those below.
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